Report: The rapid development of China's pharmaceutical innovation and the original innovation ability needs to be strengthened

Chinanews.
com, Beijing, October 29.
A few days ago, the "Building China's Pharmaceutical Innovation Ecology The main report of the System (2021-2025) was released in Beijing
.
Data map
.
The report pointed out that basic research is the source of medical innovation, and the direction of innovation should be guided from the funding and research system
.
At present, the quality and quantity of China's pharmaceutical innovation are flying at the same time.
The number of R&D pipeline products accounted for 13.
9% of the world's total.
It has jumped to the second R&D echelon in the world, but the original innovation and basic research capabilities need to be strengthened
.
According to the report, the number of China's innovative drugs approved for marketing in 2020 will be 9 times that of 2016, and the simultaneous R&D, registration and review of domestic and foreign drugs has been gradually realized
.
However, there is still a "time gap" between China's registration and approval and the world, and the proportion of participating in international multi-center clinical trials is only 9.
4%, and there is still room for improvement
.
The analysis of the report pointed out that China's improvement in the prevention and treatment of the three major types of diseases, cancer, chronic diseases, and infectious diseases, will effectively improve the health of the whole people
.
Ensuring that innovative drugs benefit more patients faster and improve medical effects is the top priority of China's pharmaceutical innovation ecosystem
.
The report also mentioned that in recent years, the frequency of updates of the medical insurance catalogue has continued to increase, and the support of medical insurance for reimbursement of innovative drugs has increased the availability of innovative drugs
.
Therefore, in order to improve the level of protection, promoting the construction of a multi-level medical security system has become the current policy focus
.
At the same time, the report emphasizes that clinical value is the core of drug research and development evaluation, and drug research and development needs to be clinically value-oriented.
High clinical value prevention methods, treatment methods and technological breakthroughs will effectively reduce the overall burden of disease in China
.
The report recommends that in order to achieve more comprehensive simultaneous research and development, it is necessary to cooperate with various regulatory agencies, enterprises and researchers, fully integrate with the international system in terms of regulatory procedures, and strengthen clinical research capabilities and professionalism.

.
Improve the efficient use of medical insurance funds, promote the integration and linkage of medical insurance and commercial insurance, and ultimately help people’s health and the high-quality development of the industry
.
Song Ruilin, executive chairman of the China Association for the Promotion of Pharmaceuticals, said that at present, a new round of technological revolution and industrial transformation is in-depth development.
After the baptism of the global epidemic and prevention and control of the new crown epidemic, the important role of pharmaceutical innovation in controlling the epidemic and restoring the economy has become more prominent.

.
Conway, the CEO of RDPAC, said that China’s pharmaceutical innovation ecosystem is currently taking shape, and breakthroughs in original innovation still require long-term accumulation and development.
In the future, we look forward to establishing a multi-level medical security system shared by the government and the market economy to promote China Joining the global early clinical layout and mutual recognition of international clinical trial data will ultimately enable patients to use innovative and good drugs as soon as possible
.
(over)